Penile Dermal Fillers in India and UAE | Complete Patient Guide

• **Ideal candidates:** Adult males (≥18 years) with stable penile anatomy, documented dissatisfaction with penile girth on validated psychosexual tools (SEAR, IIEF-5 baseline review), and realistic expectations following thorough counselling by a specialist andrologist or plastic surgeon.

• **Anatomical suitability:** Normal penile vascular supply confirmed clinically; no prior penile surgery, Peyronie's disease plaques, or penile implants that would distort filler planes.

• **Psychological eligibility:** No evidence of body dysmorphic disorder (BDD) — routinely screened using the Body Dysmorphic Disorder Questionnaire (BDDQ); absence of severe depression or untreated anxiety disorders.

• **General health requirements:** Non-smoker or willing to abstain from nicotine ≥2 weeks pre- and post-procedure (nicotine causes vasoconstriction and increases necrosis risk); no active genital infection (HSV, HPV lesions, balanitis); no blood coagulation disorders or therapeutic anticoagulation (warfarin, novel oral anticoagulants) that cannot be safely bridged.

• **Required pre-procedural assessments:** Complete blood count (CBC), coagulation screen (PT/INR, aPTT), fasting glucose and HbA1c (diabetes is a relative contraindication due to impaired healing), total testosterone and hormonal panel, STI screening (HIV, hepatitis B/C, syphilis), baseline penile Doppler ultrasound (at high-volume centres), and standardised penile measurement documentation (flaccid and stretched penile length, flaccid and erect girth at base and mid-shaft).

• **Contraindications (absolute):** Active genital or systemic infection; known hypersensitivity to hyaluronic acid or PMMA components; penile implant in situ; diagnosed BDD; minor (age <18); pregnancy or partner pregnancy where abstinence compliance cannot be assured.

• **Contraindications (relative):** Peyronie's disease with active inflammation phase; poorly controlled diabetes (HbA1c >8.5%); history of keloid scarring; severe erectile dysfunction (IIEF-5 <10) requiring concurrent pharmacological management that has not been optimised.

**1. Hyaluronic Acid (HA) Filler Injection — Current Gold Standard (Temporary, 12–24 months)** Cross-linked HA products with high G-prime (elastic modulus) — Juvederm Voluma XC, Restylane Lyft, Stylage XXL — are injected into the suprafascial plane using retrograde linear threading or fanning technique via blunt-tip microcannulas (18–22G). Typical volume per session: 10–30 mL of HA gel to achieve clinically meaningful girth increase of 1.5–3 cm in flaccid circumference. The primary advantage is full reversibility using hyaluronidase enzyme (hylenex or Vitrase), enabling dissolution of the product in cases of migration, asymmetry, or patient dissatisfaction. Sessions can be repeated or topped up without structural tissue commitment.

**2. PMMA Microsphere Fillers — Semi-Permanent Option (Ellansé, Sculptra adaptation)** Polymethylmethacrylate (PMMA) microspheres suspended in carboxymethylcellulose (CMC) carrier gel (e.g., Ellansé S/M/L/E grades) induce a controlled foreign-body fibroblast response, producing autologous collagen around the microspheres for durable augmentation lasting 2–4+ years depending on the product grade. These are not reversible with hyaluronidase; revision requires surgical excision in cases of complication. Offered at specialist centres for patients who have already tolerated HA fillers and desire durability. Requires more advanced injector expertise and carries higher granuloma risk than HA.

**3. Platelet-Rich Plasma (PRP) Adjunct — The "P-Shot" Protocol** PRP prepared from autologous venous blood (centrifuged at 1,500–3,000 RPM to yield 4–6× baseline platelet concentration) is sometimes co-administered with HA filler or used as a standalone session to stimulate tissue vascularity, support collagen remodelling, and improve erectile function scores. While evidence is still emerging (Level III–IV), the P-Shot is offered at premium centres in Dubai and Mumbai as part of a combined penile rejuvenation protocol.

**4. Blunt Microcannula vs. Sharp Needle Technique** Blunt-tip microcannulas (18–22G, 50–70 mm) are preferred over sharp 27–30G needles at high-volume centres due to significantly reduced intravascular injection risk, fewer entry points, and lower haematoma rates. Doppler-guided injection — real-time ultrasound mapping of the dorsal penile neurovascular bundle before filler deposition — is the most advanced safety protocol and is available at select JCI-accredited hospitals in India (Mumbai, Delhi, Bengaluru) and UAE (Dubai, Abu Dhabi).

**5. Surgical Fat Transfer (Autologous Lipofilling) — Surgical Alternative** For patients seeking more substantial or permanent augmentation, microfat or nanofat grafting harvested via tumescent liposuction from the abdomen or flank can be injected into the suprafascial penile plane. This is a surgical procedure requiring local or regional anaesthesia, carries risks of fat resorption (20–60%), cyst formation, and calcification, and is generally considered a second-line option relative to HA fillers for girth augmentation. Offered at plastic surgery departments within NABH/JCI hospitals.

**Phase 1 — Pre-Arrival Consultation (2–4 Weeks Before Travel)**

GAF Healthcare connects the patient with a board-certified andrologist or plastic surgeon via encrypted video teleconsultation. The specialist reviews submitted medical records, performs validated psychosexual screening (IIEF-5, SEAR, BDDQ), and determines candidacy. If approved, a personalised pre-procedure checklist is issued: cessation of NSAIDs, aspirin, vitamin E, fish oil, and herbal supplements (anticoagulant effect) ≥7 days pre-procedure; abstinence from alcohol ≥48 hours; STI and blood panel results submitted digitally for review.

**Phase 2 — Arrival and Pre-Procedure Day (Day 0)**

GAF Healthcare's airport liaison meets the patient, transfers them to partnered accommodation (private apartment or 4–5 star hotel with concierge medical support), and accompanies them to the clinic for in-person pre-procedural assessment. The treating physician performs a physical examination, confirms penile Doppler mapping if indicated, obtains written informed consent documenting expected outcomes, longevity, revision protocols, and complication management pathways. Topical eutectic anaesthetic cream (EMLA 5%) or a dorsal penile nerve block using 1% lidocaine without epinephrine is applied 45–60 minutes before injection.

**Phase 3 — The Procedure (45–90 Minutes)**

The patient is positioned supine in a sterile field. The shaft is cleansed with chlorhexidine. The injector marks the entry points for microcannula insertion (typically 2–4 entry points at the base and mid-shaft). HA filler is deposited in 0.1–0.5 mL aliquots across the suprafascial plane using retrograde threading, with intermittent tactile and visual assessment for symmetry. Manual moulding is performed throughout to ensure even distribution. Total filler volume and product batch are documented in the patient record. A light compressive dressing is applied.

**Phase 4 — Immediate Post-Procedure (Day 0–2)**

The patient rests at the accommodation facility. GAF Healthcare's clinical coordinator provides a 24-hour support line. Ice packs applied 10 minutes on/10 minutes off for the first 24 hours. Common expected findings: mild oedema (peaks at 48–72 hours), bruising, and temporary asymmetry due to swelling — all normalise within 1–2 weeks. The patient is instructed to avoid sexual activity, masturbation, and any form of penile compression for a minimum of 2 weeks.

**Phase 5 — Early Recovery (Day 3–7)**

The surgeon reviews the patient at Day 3 (in-clinic or via teleconsultation for remote patients). Moulding massage instructions are reinforced. Oral prophylactic antibiotics (typically 5-day course of amoxicillin-clavulanate or ciprofloxacin for penicillin-allergic patients) are completed. Patients with mild residual oedema or asymmetry are reassured that final results should not be assessed before Day 14–21. Fitness-to-fly assessment is conducted: if no haematoma, vascular compromise signs, or infection, short-haul flights are cleared at Day 7.

**Phase 6 — Fit-to-Fly and Departure (Day 7–14)**

Long-haul international flight clearance is issued at Day 10–14. The patient receives a detailed medical discharge summary (in English and local language if required), emergency contact protocols, and a digital copy of product batch records for any future treating physician. A 6-week teleconsultation follow-up and a 6-month photo-review session are pre-booked through GAF Healthcare's platform before departure.

**Recovery Milestones:**

• Day 1–3: Swelling and bruising peak; rest and ice.

• Day 7: Short-haul flight cleared; return to sedentary work.

• Day 14: Sexual activity can typically resume; final symmetry assessment begins.

• Day 21–30: Oedema fully resolved; final girth result assessable.

• Month 3: Touch-up session if required for volume asymmetry.

• Month 12–18: HA filler maintenance session typically indicated to maintain results.